Skip to content

Rasburicase for gout

Treatment of severe gout patients with rasburicase

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27662
Enrollment
20
Registered
2021-01-07
Start date
2021-05-03
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout

Interventions

rasburicase 0,15mg/kg, once a week during 3 months. Premedication: clemastine and methylprednisolon.

Sponsors

Sanofi, Reade foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults with severe tophaceous gout

Exclusion criteria

Exclusion criteria: non-compensated congestive heart failure, prior treatment with a recombinant uricase, pregnancy, known allergy for rasburicase or added substances as described in the SmPC of Fasurtec. Known glucose-6-phosphate dehydrogenase deficiency or other cellular metabolic disorder causing hemolytic anemia. Recipient of an investigational drug within 4 weeks prior to study drug administration.

Design outcomes

Primary

MeasureTime frame
serum uric acid (mmol/l)

Secondary

MeasureTime frame
patient related outcomes, safety measures.

Contacts

Public ContactDaisy Vedder

Reade

d.vedder@reade.nl0202421815

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)